(NP (NP (ADJP Sterol/NN dependent/JJ) LDL-receptor/NN gene/NN transcription/NN) (PP in/IN (NP (NP lymphocytes/NNS) (PP from/IN (NP (UCP-COOD (ADJP normal/JJ) and/CC (NP CML/NN)) patients/NNS)))) ./.)
(S (NP-SBJ-61 (NP Sterol/NN regulatory/JJ element/NN) (PRN -LRB-/-LRB- (NP SRE/NN) -RRB-/-RRB-)) (VP has/VBZ (VP been/VBN (VP recognized/VBN (S (NP-SBJ *-61/-NONE-) (VP to/TO (VP regulate/VB (NP (NP various/JJ key/JJ genes/NNS) (VP coding/VBG (PP for/IN (NP (NP-COOD (NP (ADJP especially/RB low/JJ) density/NN lipoprotein/NN -LRB-/-LRB- LDL/NN -RRB-/-RRB- -receptor/NN) ,/, (NP (NP 3-hydroxy-3-methylglutaryl/NN coenzyme/NN A/NN) (PRN -LRB-/-LRB- (NP HMG-CoA/NN) -RRB-/-RRB-) reductase/NN) and/CC (NP HMG-CoA/NN synthase/NN)) (VP known/VBN (S (NP-SBJ */-NONE-) (VP to/TO (VP play/VB (NP a/DT crucial/JJ role/NN) (PP in/IN (NP the/DT cholesterol/NN feedback/NN mechanism/NN)))))))))))))))) ./.)
(S (NP-SBJ-62 The/DT deranged/JJ cholesterol/NN feedback/NN mechanism/NN) (VP has/VBZ (VP been/VBN (VP (ADVP widely/RB) recognised/VBN (NP *-62/-NONE-) (PP in/IN (NP (NP-COOD (NP initiation/NN) (CONJP as/RB well/RB as/IN) (NP progression/NN)) (PP of/IN (NP (NP various/JJ types/NNS) (PP of/IN (NP cancers/NNS)) (PP including/VBG (NP (NP chronic/JJ myeloid/JJ leukaemia/NN) (PRN -LRB-/-LRB- (NP CML/NN) -RRB-/-RRB-)))))))))) ./.)
(S (ADVP Consequently/RB) ,/, (NP-SBJ-110 the/DT present/JJ study/NN) (VP-COOD (VP was/VBD (VP addressed/VBN (NP *-110/-NONE-) (S (NP-SBJ */-NONE-) (VP to/TO (VP understand/VB (NP this/DT phenomenon/NN)))))) and/CC (VP revealed/VBD (NP-COOD (NP (NP the/DT existence/NN) (PP of/IN (NP (NP a/DT unique/JJ (ADJP 47/CD kDa/NN) protein/NN factor/NN) (VP having/VBG (NP (NP affinity/NN) (PP for/IN (NP this/DT SRE/NN sequence/NN)))))) (PP in/IN (NP (NP lymphocytes/NNS) (PP from/IN (NP normal/JJ subjects/NNS))))) (CONJP as/RB well/RB as/IN) (NP (NP its/PRP$ absence/NN) (PP in/IN (NP (NP lymphocytes/NNS) (PP from/IN (NP untreated/JJ CML/NN patients/NNS)))))))) ./.)
(S (ADVP However/RB) ,/, (NP-SBJ this/DT factor/NN) (VP appeared/VBD (SBAR-TMP (WHADVP-63 when/WRB) (S (NP-SBJ the/DT CML/NN patients/NNS) (VP achieved/VBD (NP (NP complete/JJ haematological/JJ remission/NN) (PRN -LRB-/-LRB- (NP CHR/NN) -RRB-/-RRB-)) (PP through/IN (NP alpha-interferon/NN therapy/NN)) (ADVP *T*-63/-NONE-))))) ./.)
(S (ADVP Further/RB) ,/, (NP-SBJ-64 an/DT inverse/NN relationship/NN) (VP was/VBD (VP (ADVP also/RB) observed/VBN (NP *-64/-NONE-) (PP between/IN (NP-COOD (NP (ADJP sterol/NN modulated/JJ) LDL-receptor/NN gene/NN transcription/NN) and/CC (NP (NP the/DT binding/NN affinity/NN) (PP of/IN (NP this/DT (ADJP 47/CD kDa/NN) factor/NN)) (PP to/TO (NP the/DT SRE/NN sequence/NN))))))) ./.)
(S (PP Based/VBN (PP upon/IN (NP these/DT results/NNS))) (NP-SBJ we/PRP) (VP propose/VBP (SBAR that/IN (S (NP-SBJ alpha-interferon/NN) (PP through/IN (NP its/PRP$ receptor/NN)) (VP initiates/VBZ (NP (NP (ADJP (NP phosphatidic/JJ acid/NN) dependent/JJ) signalling/NN) (SBAR (WHNP-66 which/WDT) (S (PP in/IN (NP turn/NN)) (NP-SBJ *T*-66/-NONE-) (VP regulates/VBZ (NP-COOD (NP (NP the/DT affinity/NN) (PP of/IN (NP (ADJP 47/CD kDa/NN) sterol/NN regulatory/JJ element/NN binding/NN factor/NN))) (CONJP as/RB well/RB as/IN) (NP LDL-receptor/NN gene/NN transcription/NN))))) (PP in/IN (NP (NP lymphocytes/NNS) (PP from/IN (NP CML/NN patients/NNS))))))))) ./.)
